Health & Medical Cancer & Oncology

Adult Acute Myeloid Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI]-Unt

Adult Acute Myeloid Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI]-Untreated Adult Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Untreated Adult Acute Myeloid Leukemia


Adult Acute Myeloid Leukemia Treatment (PDQ®): Treatment - Health Professional Information [NCI] Guide



In contrast, a trial randomly assigned low-risk patients (age <60 years, white blood cell count [WBC] < 10,000/mm3) to receive ATRA and daunorubicin as induction therapy, followed by daunorubicin consolidation and ATRA plus mercaptopurine plus methotrexate as maintenance therapy.[41] Patients were randomly assigned to receive cytarabine in the induction and consolidation modules, or not. The trial was stopped at an early interim analysis following randomization of 172 patients. The cytarabine group demonstrated a superior 2-year relapse rate (4.7% vs. 15.9%, P = .011), 2-year EFS (93.3% vs. 77.2%, P = .002), and 2-year OS (97.9% vs. 89.6%, P = .007).[41][Level of evidence: 3iiiA] The latter study used a different chemotherapy platform than the one used by the Italian and Spanish groups, which reported no benefit to cytarabine.

Studies are beginning to examine the inclusion of arsenic trioxide (ATO) in the management of previously untreated patients. In one trial, 85 newly diagnosed patients were treated with ATRA plus ATO until remission; hydroxyurea or idarubicin and cytarabine were added if the WBC was greater than 10,000/mm3.[42] This was followed by three cycles of consolidation (ara-C plus daunorubicin, plus cytarabine, and ara-C plus homoharringtonine) and maintenance with five cycles of sequential ATRA (1 month), ATO (1 month) and 6-mercaptopurine plus methotrexate (1 month). Eighty patients achieved remission with five induction deaths. Four relapses developed between 8 months and 39 months following remission attainment, all of which were in the central nervous system (CNS). Five-year event-free survival (EFS) was 89%.[42]

In another trial, investigators used an ATO-based regimen, which included gemtuzumab ozogamicin (GO) as the only cytotoxic drug.[43] Patients received ATRA plus ATO induction; patients also received a dose of GO if the WBC was greater than 10,000/mm3 on presentation or rose to over 30,000/mm3 during induction. Patients in remission received alternating months of ATO and ATRA for a total of seven cycles; GO was substituted if either ATO or ATRA were discontinued as a result of toxicity. Eighty-two patients were treated; seven patients died during induction, the remainder achieved remission. Three patients relapsed and four patients died during remission; thus EFS was approximately 76%.
SHARE
RELATED POSTS on "Health & Medical"
Reasons Why There Is So Much Skin Cancer Now Days
Reasons Why There Is So Much Skin Cancer Now Days
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population
Mesothelioma – An Overview To A Deadly Cancer
Mesothelioma – An Overview To A Deadly Cancer
Is Massage A Natural Pain Relief?
Is Massage A Natural Pain Relief?
Could the HPV Test Replace the Pap Test?
Could the HPV Test Replace the Pap Test?
Diagnostic Tests - PET Scans
Diagnostic Tests - PET Scans
Elderly Receiving Neoadjuvant Chemoradiation for Rectal Cancer
Elderly Receiving Neoadjuvant Chemoradiation for Rectal Cancer
Routine Mammograms Found Not Helpful for Most Women Over 70
Routine Mammograms Found Not Helpful for Most Women Over 70
Meaty Diet Linked to Pancreatic Cancer
Meaty Diet Linked to Pancreatic Cancer
Advances in Transplantation Strategies for Multiple Myeloma
Advances in Transplantation Strategies for Multiple Myeloma
Bioavailability of Tyrosine Kinase Inhibitors
Bioavailability of Tyrosine Kinase Inhibitors
Tracking and Journaling the Cancer Journey
Tracking and Journaling the Cancer Journey
What You Need to Know About Benign Multicystic Mesothelioma
What You Need to Know About Benign Multicystic Mesothelioma
Essential Good Nutrition for Cancer Patients.
Essential Good Nutrition for Cancer Patients.
Stage 4 Lung Cancer - What Is It?
Stage 4 Lung Cancer - What Is It?
Wigs Help Patients Handle the Challenges of Treatment
Wigs Help Patients Handle the Challenges of Treatment
University Of Chicago Scientists Provide New Evidence For Cellular Cause Of Sids
University Of Chicago Scientists Provide New Evidence For Cellular Cause Of Sids
Oncotype DX as a Decision Tool in Early Breast Cancer
Oncotype DX as a Decision Tool in Early Breast Cancer
Practice of Medicine: Anxiety Up, Morale Down
Practice of Medicine: Anxiety Up, Morale Down
Surviving Breast Cancer - A Husband' s View
Surviving Breast Cancer - A Husband' s View
Breast Cancer Prevention Tips
Breast Cancer Prevention Tips
Journal Article: Adjuvant Chemotherapy for Stage 2 Colon Cancer
Journal Article: Adjuvant Chemotherapy for Stage 2 Colon Cancer
The D'Amico Classification System for Prostate Cancer
The D'Amico Classification System for Prostate Cancer
The Common Signs and Symptoms of Pancreatic Cancer
The Common Signs and Symptoms of Pancreatic Cancer

Leave Your Reply

*